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Introduction {#sec001}
============

Bacterial membrane vesicles were first discovered some five decades ago in Gram-negative bacteria \[[@pone.0130528.ref001]\]. These globular structures, which range in diameter from 10 to 200 nm, result from outer membrane blebbing and are called outer membrane vesicles (OMV). The biogenesis of OMVs remains unclear due to the difficulty in obtaining mutant strains that do not produce OMVs \[[@pone.0130528.ref002]\]. Over the years, many roles have been assigned to OMVs, including intercellular communication \[[@pone.0130528.ref003]\], response to environmental stresses \[[@pone.0130528.ref004]\], biofilm formation \[[@pone.0130528.ref005]\], pathogenic processes \[[@pone.0130528.ref006]\], and horizontal gene transfer \[[@pone.0130528.ref007]\]. The rising interest in bacterial membrane vesicles lead to the creation of EVpedia, a web-based database that collects published data about vesicles produced by prokaryotes and eukaryotes \[[@pone.0130528.ref008]\]. Given that OMVs contain large amounts of membrane-associated proteins and virulence factors \[[@pone.0130528.ref009]\], they are highly immunogenic and may induce immunoprotection against pathogens. This has led to a growing interest in bacterial OMVs as potential vaccine candidates \[[@pone.0130528.ref010]\]. An OMV-based *Neisseria meningitidis* vaccine has already proven its effectiveness and is currently being used to prevent meningitis \[[@pone.0130528.ref011]\].

Despite the fact that vesicles produced by Gram-negative bacteria have been extensively studied, vesicles from Gram-positive bacteria were overlooked for decades since it was thought that the rigidity of the peptidoglycan-rich cell wall would not allow vesicle blebbing \[[@pone.0130528.ref012]\]. The discovery of cytoplasmic membrane-derived vesicles, or simply membrane vesicles (MVs), in Gram-positive bacteria, suggested that vesicle production is a ubiquitous phenomenon \[[@pone.0130528.ref013]\]. They were first described in 1990 \[[@pone.0130528.ref014]\] and studied in more depth in the last decade. MV production by numerous Gram-positive bacteria as well as their putative roles in virulence have been reported for *Staphylococcus aureus* \[[@pone.0130528.ref012]\], *Bacillus* spp. \[[@pone.0130528.ref015], [@pone.0130528.ref016]\], *Listeria monocytogenes* \[[@pone.0130528.ref017]\], *Clostridium perfringens* \[[@pone.0130528.ref018]\], *Streptomyces coelicolor* \[[@pone.0130528.ref019]\] and *Streptococcus* spp. \[[@pone.0130528.ref020], [@pone.0130528.ref021]\] (for recent review, see \[[@pone.0130528.ref022]\]).

The Gram-positive bacterium *Streptococcus suis* is a major swine pathogen worldwide that mainly causes septicemia, meningitis, endocarditis, arthritis, and pneumonia \[[@pone.0130528.ref023]\]. It is also considered an emerging zoonosis agent since it can infect humans who are in close contact with diseased pigs or their byproducts \[[@pone.0130528.ref024]\]. Thirty-three serotypes have been described to date based on the composition of their capsular polysaccharides. While the serotype distribution varies depending on the geographical origins of the strains, *S*. *suis* serotype 2 is considered the most pathogenic and the most prevalent capsular type recovered from diseased pigs and humans \[[@pone.0130528.ref023], [@pone.0130528.ref024]\]. The massive use of antibiotics in the swine industry has contributed to the emergence of drug resistant strains, making *S*. *suis* infections more difficult to treat and causing increasingly severe economic losses \[[@pone.0130528.ref025]\]. It is thus essential to better understand the pathogenic process of *S*. *suis* infections in order to identify new therapeutic strategies.

In this study, we hypothesized that *S*. *suis* produces MVs that may play an important role in the pathogenesis of *S*. *suis* infections. MVs were isolated using a differential centrifugation and filtration protocol. Their protein composition was analyzed and characterized using a proteomic approach. Given that bacterial vesicles generally carry virulence factors, two virulence-associated activities were assayed. The pro-inflammatory effects of *S*. *suis* MVs on monocytes and macrophages were also investigated.

Materials and Methods {#sec002}
=====================

Bacterial strain and isolation of membrane vesicles {#sec003}
---------------------------------------------------

*S*. *suis* P1/7 was grown in Todd-Hewitt Broth (THB, Becton, Dickinson and Company, Sparks, MD, USA) at 37°C. MVs were isolated using centrifugation and filtration protocol as described by Lee *et al*. \[[@pone.0130528.ref012]\], with slight modifications. Briefly, a 1-L overnight culture of *S*. *suis* (early stationary phase) was centrifuged at 10 000 × g for 20 min at 4°C, and the supernatant was filtered through a 0.45-μm pore size cellulose nitrate membrane and then through a 0.22 μm pore size cellulose nitrate membrane to remove residual bacteria. The filtrate was centrifuged at 150 000 × g for 3 h at 4°C. The pellets were resuspended in 50 mM phosphate-buffered saline (PBS, pH 7.2), further centrifuged similarly, and stored in PBS at --20°C until used. MVs were quantified by dry weight as well as by protein content (Quick Start Bradford Assay; Bio-Rad Laboratories, Mississauga, ON, Canada) according to the manufacturer's protocol.

Transmission electron microscopy {#sec004}
--------------------------------

Vesicles were suspended in 0.1 M sodium cacodylate buffer (pH 7) containing 5% glutaraldehyde and 0.15% ruthenium red. They were then treated with 1 mg/ml of polycationic ferritin and were processed as previously described by Vanrobaeys *et al*. \[[@pone.0130528.ref026]\]. Thin sections were prepared and were observed using a JEOL 1230 transmission electron microscope at an accelerating voltage of 80 kV. A 1.27 correction factor was applied to determine MVs diameter, as suggested by Kong *et al*. \[[@pone.0130528.ref027]\].

Proteomic analysis {#sec005}
------------------

Three independent batches of *S*. *suis* MVs with a protein content of 10 μg were washed three times with 50 mM ammonium bicarbonate buffer (pH 8) using Amicon 3-kDa molecular weight cut off centrifugal filters (EMD Millipore Canada; Mississauga, ON, Canada). The samples were vacuum-dried in a Speedvac concentrator (Thermo Fisher Scientific, Waltham, MA, USA) and were stored at --20°C until they were trypsin digested. Proteins were solubilized in 25 μl of 50 mM ammonium bicarbonate containing 1% sodium deoxycholate and were heated at 95°C for 5 min. The samples were reduced by adding 0.2 mM dithiothreitol (37°C for 30 min) and were alkylated by adding 0.9 mM iodoacetamide (37°C for 20 min). Trypsin (1 μg) was then added, and the samples were incubated overnight at 37°C. Proteolytic degradation was stopped by acidification with 3% acetonitrile-1% trifluoroacetic acid (TFA)-0.5% acetic acid. Peptides were purified using C18 spin tips (Thermo Fisher Scientific) and were pooled, vacuum centrifuge-dried, and resuspended in 0.1% formic acid. Peptide samples (800 ng) were fractionated by online reversed-phase nanoscale capillary liquid chromatography (nanoLC). The fractions were analyzed by electrospray mass spectrometry (ES MS/MS; Proteomics platform of the Québec Genomic Center) using a 5600 mass spectrometer (AB Sciex, Framingham, MA, USA) equipped with an Agilent 1200 nano pump, a nanoelectrospray ion source, and a self-pack PicoFrit column (15 cm x 0.075 i.d.; New Objective, Woburn, MA, USA) packed with a Jupiter C18 phase (particle size: 5 μm; pore size: 300 Å; Phenomenex, Torrance, CA). Peptides were eluted with a linear 2--50% linear gradient of acetonitrile-0.1% formic acid for 30 min at 300 nl/min. Mass spectra were acquired using Analyst software version 1.6 with the data dependent acquisition mode (AB Sciex). Each full scan mass spectrum (400 to 1250 m/z) was followed by collision-induced dissociation of the twenty most intense ions. The dynamic exclusion was set at 3 s and the tolerance at 100 ppm.

MS/MS peak list Mascot Generic Format (MGF) files were generated using ProteinPilot version 4.5 (AB Sciex) with the Paragon and Progroup algorithms \[[@pone.0130528.ref028]\]. The MGF sample files were analyzed using Mascot version 2.4.0 (Matrix Science, London, UK). Mascot and X! Tandem were set up to search the UniRef StreptococcusSuisP17 database (version February 2014, 2039 entries) assuming trypsin digestion. Mascot and X! Tandem were searched with a fragment ion mass tolerance of 0.100 Da and a parent ion tolerance of 0.100 Da. Carbamidomethylated cysteine was specified in Mascot and X! Tandem as a fixed modification. Dehydrated N-terminus, Glu-\>pyro-Glu of the N-terminus, ammonia-loss of the N-terminus, Gln-\>pyro-Glu of the N-terminus, deamidated asparagine and glutamine, and oxidation of methionine were specified in X! Tandem as variable modifications.

Proteome Scaffold version 4.3.4 (Proteome Software Inc., Portland, OR USA) was used to validate the MS/MS-based peptide and protein identification. Peptide identification was accepted if it could established there was a 6% or greater probability that the False Discovery Rate (FDR) was less than 1% using the Peptide Prophet algorithm \[[@pone.0130528.ref029]\] with Scaffold delta-mass correction. Peptide identification was accepted if it could be established that there was a 98% or greater probability of achieving an FDR less than 1% and that the protein contained at least three identified peptides. Proteins were considered present in significant amounts when at least 30 spectra were identified. The relative abundance of proteins was determined by spectral counting. Protein probabilities were assigned by the Protein Prophet algorithm \[[@pone.0130528.ref030]\]. Proteins that contained similar peptides and could not be differentiated based on an MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins were annotated with Gene Ontology (GO) terms from gene_association.goa_uniprot (downloaded March 18, 2013) \[[@pone.0130528.ref031]\]. Protein localization was predicted using GO terms as well as the Uniprot database. Proteins containing a LPXTG motif were predicted as cell wall-anchored.

Determination of enzymatic activities {#sec006}
-------------------------------------

N-succinyl-Ala-Ala-Pro-Phe-pNa, the substrate for the *S*. *suis* subtilisin protease SspA, was dissolved at a concentration of 2 mg/ml in 50% dimethylformamide, and 20 μl was added to the wells of a 96-well microplate containing 100 μl of *S*. *suis* MVs (protein content of 300 and 80 μg/ml in PBS). Assay mixtures were incubated at 37°C for 4 h. The absorbance at 415 nm (A~415~) was then recorded using a xMark microplate reader (Bio-Rad Laboratories). DNase activity was assayed as described in a previous study \[[@pone.0130528.ref032]\]. Briefly, MVs (protein content of 64, 32, and 16 μg/ml in PBS, pH 7.5) were incubated for 4 h at 37°C in the presence of 2 μg of salmon sperm DNA (Sigma-Aldrich Canada Ltd., Oakville, ON, Canada) in 50 mM PBS. One hundred microliters of Quant-iT Pico-Green dsDNA reagent (Life Technologies Inc., Burlington, ON, Canada) prepared following the manufacturer's protocol was added to the reaction mixtures, which were then incubated for 5 min at room temperature. Fluorescence was recorded using a Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA) with the excitation and emission wavelengths set at 485 ± 20 nm and 528 ± 20 nm, respectively.

Neutrophil extracellular traps degradation {#sec007}
------------------------------------------

The human promyelocytic leukemia cell line HL60 (ATCC CCL-240) was routinely grown in RPMI-1640 medium (Life Technologies Inc.) supplemented with 10% heat-inactivatedfetal bovine serum (FBS) and 100 μg/ml of penicillin-streptomycin at 37°C in a 5% CO~2~ atmosphere. Cells (10^6^ cells/ml) were treated for 3 days with 1.25% dimethylsulfoxide (DMSO) to induce differentiation into neutrophil-like cells. The efficacy of cell differentiation was evaluated using the nitro-blue tetrazolium (NBT) assay according to Collins *et al*. \[[@pone.0130528.ref033]\], with modifications. Briefly, 500 μl of cells (5.10^6^ cells/ml) were incubated for 2 h at 37°C in the presence of 10 μg/ml of *Escherichia coli* lipopolysaccharide (LPS) and 250 μl of 0.01% NBT (Sigma-Aldrich Canada Ltd.). The reaction was stopped by adding 500 μl of 0.5 M HCl. The mixtures were centrifuged for 4 min at 10 000 × g, and the pellets were resuspended in 200 μl of DMSO. The absorbance at 550 nm (A~550~) was recorded using a xMark microplate reader (Bio-Rad Laboratories) and was compared to a negative control (non-differentiated cells). Neutrophil-like cells (100 μl, 10^6^ cells/ml) were seeded in a 96-well black wall clear bottom microplate and were treated with 0.5 μM phorbol 12-myristate 13-acetate (PMA) for 3 h at 37°C in a 5% CO~2~ atmosphere. MVs (protein content of 40, 20, 10, or 1 μg/ml) were then added to the reaction mixtures, and the samples were incubated for an additional 2 h. Extracellular DNA was labeled using 0.5 μM SYTOX Green Nucleic Acid Stain (Life Technologies Inc.) according to the manufacturer's instructions. After a 10-min incubation at room temperature, fluorescence was recorded using a Synergy 2 microplate reader (BioTek Instruments) with the excitation and emission wavelengths set at 485 ± 20 nm and 528 ± 20 nm, respectively. Unstimulated cells were used as blanks to subtract the background signal.

Activation of the NF-κB signaling pathway in monocytes and macrophages {#sec008}
----------------------------------------------------------------------

The human monoblastic leukemia cell line U937-3xκB-LUC (U937 cells stably transfected with a construct containing 3 NF-κB binding sites from the Ig κ light chain promoter coupled with the gene encoding the firefly luciferase (3x-κB-*luc*) \[[@pone.0130528.ref034]\]) was kindly provided by Dr. Rune Blomhoff (University of Oslo, Norway). The cells were routinely grown at 37°C in a 5% CO~2~ atmosphere in RPMI-1640 medium supplemented with 10% FBS, 100 μg/ml of penicillin-streptomycin, and 75 μg/ml of hygromycin B (Sigma-Aldrich Canada Ltd.). The monocytes (2.10^5^ cells/ml) were differentiated into macrophage-like cells by incubating them with 10 ng/ml PMA for 24 h. The cell culture medium was then replaced with fresh medium, and the adherent macrophage-like cells were incubated for an additional 24 h prior to use. U937-3xκB-LUC monocytes and macrophage-like cells were suspended at a concentration of 2.10^6^ cells/ml in RPMI-1640 supplemented with 1% FBS, 100 μg/ml of penicillin-streptomycin, and 75 μg/ml of hygromycin B. The cell suspensions (50 μl) were seeded into wells of black bottom, black wall 96-well microplates. Two-fold serial dilutions of *S*. *suis* MVs (protein content ranging from 80 to 0.02 μg/ml) were prepared in cell culture medium, and 50 μl of each dilution was added to the wells. The microplates were incubated for 6 h at 37°C in a 5% CO~2~ atmosphere. *E*. *coli* LPS (10 μg/ml) and *S*. *suis* P1/7 whole cells (multiplicity of infection \[MOI\] of 100) were used as positive controls. NF-κB activation was monitored using the Bright-Glo Luciferase Assay System (Promega, Madison, WI, USA) by adding 100 μl of luciferase substrate to the wells at room temperature. Luminescence was recorded using the luminometer option of a Synergy 2 microplate reader (BioTek Instruments) within 3 min of the addition of the substrate.

Cytokine secretion by macrophages {#sec009}
---------------------------------

The human monoblastic leukemia U937 cell line was cultivated in RPMI-1640 supplemented with 10% FBS and 100 μg/ml of penicillin-streptomycin at 37°C in a 5% CO~2~ atmosphere. The cells were then differentiated into adherent macrophage-like cells as described above. Macrophage-like cells (10^6^ cells/ml) were seeded in 6-well cell culture plates (2 ml/well) and were incubated overnight to allow adherence. The cell culture medium was aspirated and was replaced with *S*. *suis* P1/7 cell suspensions at an MOI of 100 (positive control) or *S*. *suis* MVs (protein content of 40, 20, 10, or 1 μg/ml) prepared in RPMI-1640 supplemented with 1% FBS and 100 μg/ml of penicillin-streptomycin. Following a 24-h incubation at 37°C in a 5% CO~2~ atmosphere, the culture supernatants were collected and were used to quantify interleukin (CXCL)-8, tumor necrosis factor (TNF)-α, and interleukin (IL)-1β using enzyme-linked immunosorbent assay (ELISA) kits following the manufacturer's protocols (eBioscience Inc., San Diego, CA, USA).

Statistical analysis {#sec010}
--------------------

All assays were performed in triplicate, and the means ± standard deviations were calculated. Differences were analyzed for statistical significance using the Student's t-test and were considered significant at *p* \< 0.05.

Results {#sec011}
=======

Transmission electron microscopic observations of overnight cultures of *S*. *suis* P1/7 revealed the presence of membranous globular structures, suggesting that *S*. *suis* P1/7 produces MVs ([Fig 1A](#pone.0130528.g001){ref-type="fig"}). The MVs were isolated using a differential centrifugation and filtration protocol. The average recovery rate was 4 mg of MVs (dry weight) per liter of overnight culture, which corresponded to approximately 300 μg of vesicular protein content. As shown in [Fig 1B](#pone.0130528.g001){ref-type="fig"}, the MVs appeared to be coated with a dense structure, most likely capsular material, and ranged from 13 to 130 nm in diameter.

![Transmission electron micrographs of an overnight culture of *S*. *suis* P1/7 (panel A) and the membrane vesicle preparation (panel B).\
Black arrow: whole bacterium; white arrows: membrane vesicles.](pone.0130528.g001){#pone.0130528.g001}

Proteomic sequencing detected 46 proteins in *S*. *suis* P1/7 MVs, which are listed in [Table 1](#pone.0130528.t001){ref-type="table"} by their abundance in each functional group. Only proteins that were detected in at least two batches of MVs and counting 30 or more spectra were considered. Proteins identified using the *S*. *suis* P1/7 genome database were either cytoplasmic (n = 11), membrane/cell wall-associated (n = 12), periplasmic (n = 3) or secreted (n = 4). However, the location of 16 proteins could not be assigned ([Fig 2A](#pone.0130528.g002){ref-type="fig"}). The biological activities associated with *S*. *suis* P1/7 vesicular proteins were mostly involved in the carbohydrate metabolism (n = 10), molecule transport (n = 10), catalytic activities (n = 6), gene expression (n = 4), ribosomal structure (n = 3), protein biosynthesis and arrangement (n = 4), ion binding (n = 1), oxydoreduction (n = 1), nucleotide metabolism (n = 1), and 6 proteins were of unknown function ([Fig 2B](#pone.0130528.g002){ref-type="fig"}). In addition, 9 proteins (19.6%) were identified as proven or suspected virulence factors ([Table 2](#pone.0130528.t002){ref-type="table"}), seven of which were located at the cell surface (either cell wall- or membrane-associated) and two were secreted. For the 46 proteins, in terms of relative abundance, the subtilisin-like protease SspA predominated in the MVs, followed by a putative lipoprotein (component of an ABC transporter), the cell wall-anchored DNase SsnA, the IgM protease Ide, putative exported ribonucleases (G and E), a putative N-acetylmuramoyl-L-alanine amidase, the Plr adhesin (glyceraldehyde-3-phosphate dehydrogenase), a putative sugar binding protein, the peptide binding protein OppA, the histidine triad-family protein HtpsC, the muraminidase-released protein Mrp, the elongation factor Tu, a fumarate reductase flavoprotein subunit, an unidentified putative exported protein, and a putative ABC transporter component. Interestingly, of the 15 most abundant proteins identified in the MVs, six are considered virulence factors (SspA, SsnA, Ide, Plr, HtpsC, and Mrp).

10.1371/journal.pone.0130528.t001

###### Protein content of *S*. *suis* P1/7 membrane vesicles identified by ES MS/MS in order of abundance in each functional group.

![](pone.0130528.t001){#pone.0130528.t001g}

  Protein accession number                                                 Gene accession number   MS/MS identification                                        Molecular weight   Protein name/function                     Predicted localization
  ------------------------------------------------------------------------ ----------------------- ----------------------------------------------------------- ------------------ ----------------------------------------- ------------------------
  **Translational**, **ribosomal structure**, **and biogenesis (n = 3)**                                                                                                                                                    
  C5VVU1                                                                   SSU0721                 Putative 30S ribosomal protein S1                           44 kDa             30S Ribosomal protein S1                  Cytoplasm
  C5VWE9                                                                   SSU1935                 30S ribosomal protein S4                                    23 kDa             30S Ribosomal protein S4                  Cytoplasm
  C5VVK7                                                                   SSU1771                 30S ribosomal protein S2                                    29 kDa             30S Ribosomal protein S2                  Cytoplasm
  **Transport**, **uptake**, **and osmoregulation (n = 9)**                                                                                                                                                                 
  C5VWT7                                                                   SSU0934                 Putative lipoprotein                                        36 kDa             Putative ABC transporter                  Membrane
  C5W096                                                                   SSU1664                 Putative oligopeptide-binding protein OppA                  66 kDa             OppA / Peptide binding                    Unknown
  C5W029                                                                   SSU0503                 Putative amino acid ABC transporter                         31 kDa             ABC transporter                           Unknown
  C5VW03                                                                   SSU1853                 Putative amino-acid ABC transporter                         29 kDa             ABC transporter                           Periplasm
  C5VXJ7                                                                   SSU1170                 Extracellular solute-binding protein                        61 kDa             Sugar ABC transporter                     Secreted
  C5VW19                                                                   SSU1869                 Extracellular metal cation-binding protein                  36 kDa             ZnuA / Zinc uptake                        Secreted
  C5VZZ1                                                                   SSU0465                 Putative exported protein                                   41 kDa             Predicted membrane fusion protein         Membrane
  C5VYV7                                                                   SSU0284                 Extracellular solute-binding protein                        35 kDa             ABC transporter                           Periplasm
  C5VYN9                                                                   SSU1364                 Branched-chain amino acid ABC transporter                   41 kDa             ABC transporter                           Periplasm
  **Protein biosynthesis (n = 2)**                                                                                                                                                                                          
  C5VXU6                                                                   SSU1196                 Threonine-tRNA ligase                                       75 kDa             ThrS / protein biosythesis                Cytoplasm
  C5VZL9                                                                   SSU0412                 Valine-tRNA ligase                                          101 kDa            ValS / protein biosynthesis               Cytoplasm
  **Carbohydrate/sugar metabolism (n = 10)**                                                                                                                                                                                
  C5VXF6                                                                   SSU1127                 Putative N-acetylmuramoyl-L-alanine amidase                 113 kDa            Peptidoglycan catabolism                  Unknown
  C5VY36                                                                   SSU0153                 Glyceraldehyde-3-phosphate dehydrogenase                    39 kDa             Plr / adhesin                             Secreted
  C5VWC9                                                                   SSU1915                 Putative maltose/maltodextrin-binding protein               44 kDa             sugar binding                             Membrane
  C5VWE7                                                                   SSU1933                 Putative fumarate reductase flavoprotein subunit            53 kDa             Fumarate reductase flavoprotein subunit   Unknown
  C5VXV7                                                                   SSU1207                 Putative lipoprotein                                        30 kDa             Predicted glucose-6-phosphate isomerase   Unknown
  C5VVZ9                                                                   SSU1849                 Putative surface-anchored amylopullulanase                  234 kDa            ApuA / amylopullulanase / Adhesin         Cell wall
  C5VY37                                                                   SSU0154                 Phosphoglycerate kinase                                     42 kDa             Phosphoglycerate kinase                   Cytoplasm
  C5VYJ5                                                                   SSU1320                 Enolase                                                     47 kDa             Eno / adhesin                             Cell wall
  C5VYP7                                                                   SSU1372                 Multiple sugar-binding protein                              45 kDa             Sugar transporter                         Unknown
  C5VZ34                                                                   SSU1451                 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase   26 kDa             GpmA / glycolytic process                 Unknown
  **Nucleotide metabolism (n = 1)**                                                                                                                                                                                         
  C5VX44                                                                   SSU1044                 Ribonucleoside-diphosphate reductase                        82 kDa             DNA synthesis                             Cytoplasm
  **Protein folding/arranging (n = 2)**                                                                                                                                                                                     
  C5VX75                                                                   SSU1078                 Foldase protein PrsA                                        38 kDa             PrsA / protein folding                    Membrane
  C5VXK4                                                                   SSU1177                 Peptidyl-prolyl cis-trans isomerase                         28 kDa             Protein folding                           Unknown
  **Gene expression (n = 4)**                                                                                                                                                                                               
  C5W008                                                                   SSU0482                 Elongation factor Tu                                        44 kDa             TufA / elongation factor Tu               Cytoplasm
  C5VY08                                                                   SSU0123                 DNA-directed RNA polymerase subunit beta                    136 kDa            DNA-dependant RNA polymerase              Cytoplasm
  C5VY34                                                                   SSU0151                 Elongation factor G                                         77 kDa             FusA / elongation factor G                Cytoplasm
  C5VY07                                                                   SSU0122                 DNA-directed RNA polymerase subunit beta                    133 kDa            RpoB / RNA-polymerase                     Cytoplasm
  **Catalytic activity (n = 5)**                                                                                                                                                                                            
  C5VVK9                                                                   SSU1773                 Putative surface-anchored serine protease                   187 kDa            SspA / Subtilisin-like protease           Cell wall
  C5VVJ6                                                                   SSU1760                 Surface-anchored DNA nuclease                               114 kDa            SsnA / Nuclease                           Cell wall
  C5W022                                                                   SSU0496                 Putative Mac family protein                                 124 kDa            IgM protease                              Membrane
  C5W049                                                                   SSU1616                 Putative exported protein                                   122 kDa            Predicted ribonuclease G and E            Unknown
  C5VXH2                                                                   SSU1143                 Putative surface-anchored zinc carboxypeptidase             118 kDa            Surface anchored zinc carboxypeptidase    Cell wall
  **Defense/virulence mechanisms (n = 4)**                                                                                                                                                                                  
  C5VYR5                                                                   SSU1390                 Streptococcal histidine triad-family protein                96 kDa             HtpsC                                     Cell wall
  C5VVS8                                                                   SSU0706                 Muramidase-released protein                                 136 kDa            Mrp                                       Cell wall
  C5VZA8                                                                   SSU0370                 Putative penicillin-binding protein 1A                      79 kDa             Pbp1A / Penicillin-binding protein        Unknown
  C5VXY1                                                                   SSU1231                 Suilysin                                                    55 kDa             Sly / Hemolysin                           Secreted
  **Ion binding (n = 1)**                                                                                                                                                                                                   
  C5VY00                                                                   SSU0115                 Zinc-binding protein AdcA                                   56 kDa             AdcA/Zinc-binding protein                 Unknown
  **Redox (n = 1)**                                                                                                                                                                                                         
  C5VYT4                                                                   SSU0261                 Aldehyde-alcohol dehydrogenase                              97 kDa             Oxydoreductase                            Unknown
  **Uncharacterized proteins (n = 4)**                                                                                                                                                                                      
  C5VV38                                                                   SSU0595                 Putative exported protein                                   13 kDa                                                       Unknown
  C5VZS6                                                                   SSU1560                 Putative lipoprotein                                        17 kDa                                                       Unknown
  C5VV37                                                                   SSU0594                 Putative exported protein                                   14 kDa                                                       Unknown
  C5VV35                                                                   SSU0592                 Putative exported protein                                   12 kDa                                                       Unknown

10.1371/journal.pone.0130528.t002

###### Virulence factors identified in *S*. *suis* P1/7 membrane vesicles.

![](pone.0130528.t002){#pone.0130528.t002g}

  Identified proteins                            Factor   Protein accession number   Gene accession number   Molecular weight   Function                   References
  ---------------------------------------------- -------- -------------------------- ----------------------- ------------------ -------------------------- ----------------------------------------------------
  Surface-anchored serine protease               SspA     C5VVK9                     SSU1773                 187 kDa            Subtilisin-like protease   \[[@pone.0130528.ref039], [@pone.0130528.ref040]\]
  Surface-anchored DNA nuclease                  SsnA     C5VVJ6                     SSU1760                 114 kDa            DNase                      \[[@pone.0130528.ref041], [@pone.0130528.ref042]\]
  Mac family protein                             Ide      C5W022                     SSU0496                 124 kDa            IgM protease               \[[@pone.0130528.ref038]\]
  Glyceraldehyde-3-phosphate dehydrogenase       Plr      C5VY36                     SSU0153                 39 kDa             Adhesin                    \[[@pone.0130528.ref046]\]
  Streptococcal histidine triad-family protein   HtpsC    C5VYR5                     SSU1390                 96 kDa             Unknown                    \[[@pone.0130528.ref037]\]
  Muramidase-released protein                    Mrp      C5VVS8                     SSU0706                 136 kDa            Unknown                    \[[@pone.0130528.ref043]\]
  Surface-anchored amylopullulanase              ApuA     C5VVZ9                     SSU1849                 234 kDa            Adhesin                    \[[@pone.0130528.ref044]\]
  Enolase                                        Eno      C5VYJ5                     SSU1320                 47 kDa             Adhesin                    \[[@pone.0130528.ref045]\]
  Suilysin                                       Sly      C5VXY1                     SSU1231                 55 kDa             Hemolysin                  \[[@pone.0130528.ref047], [@pone.0130528.ref048]\]

![General locations (A) and functions (B) of proteins identified in *S. suis* P1/7 membrane vesicles by ES MS/MS.](pone.0130528.g002){#pone.0130528.g002}

Based on the subtilisin and DNase assays performed to confirm the presence of active virulence factors in *S*. *suis* P1/7 MVs, only the highest concentration of MVs (300 μg/ml in protein content) displayed subtilisin activity ([Fig 3A](#pone.0130528.g003){ref-type="fig"}). On the other hand, the MVs dose-dependently degraded DNA ([Fig 3B](#pone.0130528.g003){ref-type="fig"}). More specifically, at a concentration of 64 μg/ml in protein content, the MVs degraded approximately 90% of the DNA whereas whole bacteria (OD~660~ = 1) only degraded 20% after a 4 h incubation.

![Determination of subtilisin (A) and DNase (B) activities in *S. suis* membrane vesicles.\
\*: *p* \< 0.05 compared to negative controls.](pone.0130528.g003){#pone.0130528.g003}

Given that *S*. *suis* MVs possessed strong DNase activity, we hypothesized that such structures may induce the degradation of neutrophil extracellular traps (NETs), which consist of DNA as a backbone with embedded histones, antimicrobial peptides, and proteases, and which are part of the first innate immune response at sites of infection \[[@pone.0130528.ref035]\]. As shown in [Fig 4](#pone.0130528.g004){ref-type="fig"}, MVs at a concentration as low as 1 μg/ml in protein content caused the degradation of approximately 70% of extracellular DNA excreted by NETs.

![Quantification of NET degradation by *S*. *suis* membrane vesicles.\
NETs were formed by the PMA-stimulated promyelocytic leukemia cell line HL60. \*: *p* \< 0.05 compared to the negative control (no NET degradation).](pone.0130528.g004){#pone.0130528.g004}

To explore the potential contribution of MVs to the inflammatory process associated with *S*. *suis* infections such as meningitis, NF-κB activition was monitored in monocytes and macrophages transfected with a luciferase reporter gene. NF-κB was dose-dependently activated by MVs following a 6-h stimulation of the monocytes and PMA-differentiated macrophages ([Fig 5](#pone.0130528.g005){ref-type="fig"}). More specifically, in the presence of 0.02 μg/ml (protein content) of MVs, NF-κB activity increased 2- and 2.5-fold compared to unstimulated monocytes and macrophage-like cells, respectively. In the presence of 40 μg/ml (protein content) MVs, NF-κB activity in monocytes and macrophages increased 137- and 82-fold, respectively, while *S*. *suis* P1/7 whole cells at an MOI of 100 increased NF-κB activity by approximately 10-fold in both monocytes and macrophage-like cells. Used as a positive control, *E*. *coli* LPS (10 μg/ml), which is a strong pro-inflammatory inducer, caused a 100- and 60-fold increase in NF-κB activity in monocytes and macrophages, respectively.

![Quantification of NF-κB activation in U937-3xκB-LUC monocytes (A) and macrophage-like cells (B) by *S. suis* membrane vesicles (0.01 to 40 μg/ml), *E. coli* LPS (10 μg/ml), and S. suis P1/7 whole bacteria (MOI = 100).\
Results were considered significant at §: *p* \< 0.05, \*: *p* \< 0.01, and \#: *p* \< 0.001 compared to unstimulated cells.](pone.0130528.g005){#pone.0130528.g005}

PMA-differentiated U937 cells were stimulated in the presence of *S*. *suis* MVs in order to correlate the increased NF-κB activity observed in the U937-3xκB-LUC cell line with the secretion of pro-inflammatory cytokines. As shown in [Fig 6](#pone.0130528.g006){ref-type="fig"}, *S*. *suis* MVs dose-dependently increased the secretion of CXCL-8, TNF-α, and IL-1β. For example, 40 μg/ml protein content) of MVs increased the secretion of CXCL-8, TNF-α, and IL-1β by macrophage-like cells 4.6-, 5.9-, and 5.4-fold, respectively, compared to the amounts secreted when *S*. *suis* P1/7 whole cells (MOI = 100) alone were used to stimulate the macrophage-like cells.

![Quantification of CXCL-8 (A), TNF-α (B), and IL-1β (C) secretion by macrophage-like cells stimulated with *S. suis* membrane vesicles (1 to 40 μg/ml), *E. coli* LPS (10 μg/ml), and *S. suis* P1/7 whole bacteria (MOI = 100).\
Results were considered significant at \**p* \< 0.05 compared to unstimulated cells.](pone.0130528.g006){#pone.0130528.g006}

Discussion {#sec012}
==========

Despite significant advances in our understanding of the pathogenic process of *S*. *suis* infections, major unresolved issues remain, and consequently additional studies are required to better characterize the pathogenic strategies of this swine and zoonotic pathogen. In the present study, we hypothesized that *S*. *suis* produces MVs as it has been observed with other pathogenic streptococci \[[@pone.0130528.ref020], [@pone.0130528.ref021]\]. Transmission electron microscopic observations of overnight cultures showed that *S*. *suis* P1/7 releases extracellular MVs during normal growth. MVs with diameters ranging from 13 to 130 nm were isolated from a culture supernatant of *S*. *suis* P1/7 using a simple differential centrifugation and filtration protocol. The MVs appeared to be coated by capsular material that may have bound to the vesicles during the blebbing process. Since MVs were isolated without the use of gradient centrifugation, one should not exclude that this capsular-like material could contain remaining cellular debris, even though isolated MVs were washed once in PBS. Given the relatively low vesicle yield, further studies are required to determine the growth conditions that will increase the production of MVs by *S*. *suis*.

A proteomic analysis of the *S*. *suis* MVs identified 46 proteins that participate in a broad array of functions, including molecule transport, protein, carbohydrate, and nucleotide metabolism, gene expression and protein folding processes. MVs produced by *S*. *aureus* \[[@pone.0130528.ref036]\] and *S*. *pneumoniae* \[[@pone.0130528.ref021]\] were reported to contain 143 and 211 proteins, respectively. Like *S*. *aureus* and *S*. *pneumoniae* MVs, *S*. *suis* MVs contain mainly cytoplasmic proteins as well as some membrane and cell wall proteins.

Nine proteins that are proven or suspected virulence factors were identified in *S*. *suis* MVs, including seven surface proteins (two membrane-bound: HtpsC \[[@pone.0130528.ref037]\], Ide \[[@pone.0130528.ref038]\]; and five cell wall-anchored: SspA \[[@pone.0130528.ref039], [@pone.0130528.ref040]\], SsnA \[[@pone.0130528.ref041], [@pone.0130528.ref042]\], Mrp \[[@pone.0130528.ref043]\], ApuA \[[@pone.0130528.ref044]\] and Eno \[[@pone.0130528.ref045]\]), and two extracellular proteins (Plr \[[@pone.0130528.ref046]\] and Sly \[[@pone.0130528.ref047], [@pone.0130528.ref048]\]). The two most abundant virulence factors in MVs were the subtilisin protease SspA and the cell wall-anchored DNase SsnA, which were also among the most abundant proteins overall in *S*. *suis* MVs. Biological assays confirmed the presence of both subtilisin and DNase activities in MVs. SspA can degrade the Aα chain of fibrinogen and has been suggested to play a key role in the pathogenicity of *S*. *suis* since an SspA-deficient mutant is avirulent in a standard mouse model \[[@pone.0130528.ref040]\]. Moreover, recombinant SspA induces the secretion of major pro-inflammatory cytokines and, when present in high concentrations, degrades CCL5 and IL-6 \[[@pone.0130528.ref049]\]. SsnA is the most important cell surface DNase in *S*. *suis* and may also be an important virulence factor since an SsnA-deficient mutant has been shown to be susceptible to predation in an amoebae virulence model \[[@pone.0130528.ref032]\]. Vesicle-associated DNase activity has been previously identified in OMVs secreted by the periodontopathogenic bacterium *Porphyromonas gingivalis* \[[@pone.0130528.ref050]\]. Given that SsnA allows bacteria to escape killing by NETs through the degradation of the DNA backbone \[[@pone.0130528.ref042]\], we investigated the ability of *S*. *suis* MVs to degrade NETs produced by PMA-stimulated neutrophils. *S*. *suis*-derived MVs dose-dependently degraded extracellular DNA, suggesting that MVs produced by *S*. *suis* may play an important role in the ability of the bacteria to escape NETs.

Given that extracellular vesicles can deliver bacterial effectors to host cells, several studies have shown that these structures can modulate the host immune response \[[@pone.0130528.ref051]--[@pone.0130528.ref053]\]. The monocytic U937-3xκB-LUC cell line was used to monitor the activation of the NF-κB signaling pathway in order to characterize the immunogenic properties of *S*. *suis* MVs. The MVs dose-dependently increased NF-κB activity in both monocytes and PMA-differentiated macrophage-like cells. This is in agreement with a study showing that OMVs produced by *Escherichia coli* can activate the NF-κB pathway in endothelial cells \[[@pone.0130528.ref051]\]. Since the NF-κB signaling pathway mediates the secretion of several pro-inflammatory cytokines \[[@pone.0130528.ref054]\], we assayed cytokine secretion by PMA-differentiated U937 cells stimulated with *S*. *suis* MVs. The MVs dose-dependently stimulated CXCL-8, TNF-α, and IL-1β secretion by the U937 cells, which is in agreement with the results reported by Jun et al. (2013), who showed that OMVs secreted by *Acinetobacter baumannii*, an opportunistic pathogen, elicit a pro-inflammatory response via surface-exposed proteins both *in vitro* and *in vivo* \[[@pone.0130528.ref055]\]. Gram-positive MVs not only carry virulence factors and bacterial effectors \[[@pone.0130528.ref015], [@pone.0130528.ref056]\], but can also act as delivery systems for these molecules towards host cells inducing pro-inflammatory pathways that can lead to cellular death \[[@pone.0130528.ref018], [@pone.0130528.ref036], [@pone.0130528.ref052]\]. The activation of host cells by *S*. *suis* MVs may result from the interactions of vesicular constituents, which likely contain pathogen-associated molecular patterns (PAMPs) with Toll-like receptors (TLRs) as previously shown for MVs secreted by *S*. *aureus* \[[@pone.0130528.ref052]\]. Since the host inflammatory response is very important in bacterial meningitis \[[@pone.0130528.ref057]\], the immuno-modulatory activity of *S*. *suis* MVs may contribute to the etiopathogenic process of the disease. The accumulation of pro-inflammatory mediators can affect the permeability of the blood brain barrier during meningitis. Increasing the permeability of the blood brain barrier facilitates the migration of bacteria to the central nervous system and may promote disease progression and severity \[[@pone.0130528.ref058]\].

To the best of our knowledge, while more than twenty-five Gram-negative bacterial species have been shown to produce OMVs \[[@pone.0130528.ref059]\], the release of MVs by Gram-positive bacteria has been reported for much fewer species, including *Bacillus anthracis* \[[@pone.0130528.ref015]\], *Bacillus subtilis* \[[@pone.0130528.ref016]\], *C*. *perfringens* \[[@pone.0130528.ref018]\], *L*. *monocytogenes* \[[@pone.0130528.ref017]\], *S*. *aureus* \[[@pone.0130528.ref012]\], *S*. *mutans* \[[@pone.0130528.ref020]\], and *S*. *pneumoniae* \[[@pone.0130528.ref021]\]. The present study reports for the first time that *S*. *suis* produces MVs that carry large amounts of proteins and active virulence factors and that may reach areas not accessible to whole bacteria. In addition, MVs may compete for antibodies and impede specific antibacterial immune defenses.

The emergence of drug-resistant strains of *S*. *suis* due to the widespread and inappropriate use of antibiotics by the swine industry is a major economic and public health concern \[[@pone.0130528.ref060]\]. Because of this, it is important to explore the fundamental pathogenic mechanisms of *S*. *suis* involved during infections in order to identify new candidates for treating *S*. *suis* infections and developing effective vaccines. Since *S*. *suis* MVs present a broad array of antigens, they may be a potential candidate for designing vaccines for passive antibody-based therapeutic strategies. Extracellular bacterial vesicles activate immune responses and induce immunological memories \[[@pone.0130528.ref011], [@pone.0130528.ref059]\]. For example, it has recently been shown that MVs released by *S*. *pneumoniae* induce a protective immune response and protect mice against infections by a virulent strain \[[@pone.0130528.ref021]\]. Further characterization of the composition and immunogenicity of *S*. *suis* MVs is required to better evaluate the potential of these structures for the development of an effective acellular vaccine to prevent *S*. *suis* infections.
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